Literature DB >> 17315023

JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders.

K Ohyashiki, Y Aota, D Akahane, A Gotoh, J H Ohyashiki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17315023     DOI： 10.1038/sj.leu.2404604

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  4 in total

1.  Leukocytosis is linked to thrombosis at diagnosis, while JAK2 V617F mutation is associated with thrombosis during the course of essential thrombocythemia.

Authors:  Kazuma Ohyashiki; Toru Kiguchi; Yoshikazu Ito; Hiroaki Fujimoto; Akihiko Gotoh; Tetsuzo Tauchi; Keisuke Miyazawa; Yukihiko Kimura; Junko H Ohyashiki
Journal:  Int J Hematol       Date:  2008-05       Impact factor: 2.490

2.  Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia.

Authors:  Young-Uk Cho; Hyun-Sook Chi; Eun-Hye Lee; Seongsoo Jang; Chan-Jeoung Park; Eul-Ju Seo
Journal:  Int J Hematol       Date:  2008-12-18       Impact factor: 2.490

3.  Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation.

Authors:  Matjaz Sever; Hagop Kantarjian; Sherry Pierce; Nitin Jain; Zeev Estrov; Jorge Cortes; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2009-08-29       Impact factor: 2.490

4.  The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.

Authors:  Junko H Ohyashiki; Masayuki Yoneta; Hisashi Hisatomi; Tamiko Iwabuchi; Tomohiro Umezu; Kazuma Ohyashiki
Journal:  BMC Med Genet       Date:  2012-01-17       Impact factor: 2.103
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.